Abionyx Pharma SA (ABNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has a cash flow conversion efficiency ratio of -0.314x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.70 Million ≈ $-1.99 Million USD) by net assets (€5.41 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Abionyx Pharma SA market capitalisation for the company's overall valuation and market capitalisation.
Abionyx Pharma SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Abionyx Pharma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abionyx Pharma SA ranked by their cash flow conversion efficiency. Explore Abionyx Pharma SA cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bullpen Parlay Acquisition Co
NASDAQ:BPAC
|
-0.005x |
|
Yusin Holding Corp
TW:4557
|
0.042x |
|
Act Co Ltd
KQ:138360
|
-0.024x |
|
LITHIUM IONIC CORP.
F:H3N
|
-0.182x |
|
Sungdo Engineering & Construction Co. Ltd
KQ:037350
|
0.021x |
|
Real Estate & E-Commerce Split Corp
TO:RS
|
-0.015x |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
-0.120x |
|
Adrad Holdings Ltd
AU:AHL
|
0.050x |
Annual Cash Flow Conversion Efficiency for Abionyx Pharma SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Abionyx Pharma SA from 2013 to 2024. View Abionyx Pharma SA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €7.42 Million ≈ $8.68 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.485x | -3.88% |
| 2023-12-31 | €7.92 Million ≈ $9.26 Million |
€-3.70 Million ≈ $-4.32 Million |
-0.467x | +0.37% |
| 2022-12-31 | €7.17 Million ≈ $8.38 Million |
€-3.36 Million ≈ $-3.93 Million |
-0.469x | +25.24% |
| 2021-12-31 | €10.68 Million ≈ $12.48 Million |
€-6.69 Million ≈ $-7.82 Million |
-0.627x | -593.63% |
| 2020-12-31 | €6.63 Million ≈ $7.75 Million |
€-599.00K ≈ $-700.29K |
-0.090x | +84.75% |
| 2019-12-31 | €6.67 Million ≈ $7.79 Million |
€-3.95 Million ≈ $-4.62 Million |
-0.593x | +62.11% |
| 2018-12-31 | €3.84 Million ≈ $4.49 Million |
€-6.00 Million ≈ $-7.02 Million |
-1.564x | -52.89% |
| 2017-12-31 | €8.89 Million ≈ $10.39 Million |
€-9.09 Million ≈ $-10.63 Million |
-1.023x | +22.15% |
| 2016-12-31 | €14.61 Million ≈ $17.08 Million |
€-19.20 Million ≈ $-22.44 Million |
-1.314x | -218.16% |
| 2015-12-31 | €33.20 Million ≈ $38.81 Million |
€-13.71 Million ≈ $-16.03 Million |
-0.413x | +99.85% |
| 2014-12-31 | €12.00K ≈ $14.03K |
€-3.30 Million ≈ $-3.86 Million |
-275.250x | -11602.83% |
| 2013-12-31 | €6.16 Million ≈ $7.20 Million |
€-14.49 Million ≈ $-16.94 Million |
-2.352x | -- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more